Abstract Details

Title The relationship among leptomeningeal enhancement clinical activity and cerebrospinal fluid markers

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 165

Objective

To assess in-vivo prevalence of LME in relapsing-remitting MS (RRMS) and to evaluate its association with cerebrospinal fluid (CSF) markers.

Background Meningeal inflammation is a progressively recognized finding in multiple sclerosis (MS). The real prevalence of leptomeningeal enhancement (LME) in MS and its association with neurodegeneration is still a matter of debate.

Design/Methods LME was assessed on a 3 Tesla MRI with a 3D 1x1x1 mm³ Fluid-Attenuated-Inversion-Recovery (FLAIR) acquired 20 minutes post gadolinium administration (TR 6000 ms; TE 356 ms; Fat suppressed). LME was defined as signal intensity within subarachnoid space greater than that of brain parenchyma and brighter on post-contrast scans. For each patient we collected CSF parameters at diagnosis: protein, cells, serum and CSF albumin, serum and CSF IgG, link index, immunoblotting and number of oligo-clonal bands. Differences in terms of clinical and CSF metrics between patients with and without LME were tested with ANOVA, chi square and binary logistic regression analysis as appropriate.

Results 38 RRMS patients were included in the analysis: [65,2% female, mean age 37,8±10.1 years mean disease duration 10,1±9.2 years, median Expanded-Disability-Status-Scale (EDSS) 2 (0-6,5)]. LME was present in 37% of patients, median number 1 (1-3). No difference in EDSS, age, disease duration was found between patients with or without nodules. CSF parameters had no predictive value for LME development nor any association was found between presence of oligo-clonal bands and LME.

Conclusions LME was found in a discrete proportion of RRMS patients and it was not associated with the presence of oligo-clonal bands nor other CSF parameters.

Authors/Disclosures
Nicolo Bruschi PRESENTER	Mr. Bruschi has nothing to disclose.
Caterina Lapucci, MD (DINOGMI, University of Genoa)	Dr. Lapucci has nothing to disclose.
	No disclosure on file
Giacomo Boffa (Department of Neuroscience, University of Genova)	Mr. Boffa has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Elisabetta Capello, MD (Ospedale San Martino - Clinica Neurologica)	No disclosure on file
Matilde Inglese, MD, PhD (University of Genoa)	Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.

��ɫ��

��ɫ��